Quantcast

Latest glioblastoma multiforme Stories

2014-07-15 08:28:10

Physicians at 15 leading brain cancer centers in 8 countries certified to provide NovoTTF Therapy to recurrent glioblastoma patients on prescription order LUCERNE, Switzerland, July 15, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that 18 prominent neurosurgeons and neuro-oncologists at medical centers in Europe and Israel are trained and certified to prescribe NovoTTF Therapy. These physicians will now be able to treat recurrent glioblastoma...

2014-07-14 08:26:37

SAN ANTONIO, July 14, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Kareg Corporation's Director of Research, Sheldon S. Traube, has issued the following research report on the company. Sheldon S. Traube, Director of Research, Kareg Corporation, Initiating Coverage with a Speculative Buy Recommendation Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf...

2014-07-12 23:02:37

ResearchMoz presents this most up-to-date research on Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market. View All Therapeutic Area Market Research Reports at http://www.researchmoz.us/therapeutic-area-market-reports-37.html. Albany, NY (PRWEB) July 12, 2014 “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive...

2014-07-11 23:09:19

Capital Institute for Neurosciences Begins Clinical Trial Delivering Chemotherapy Directly to Brain Tumors Starting with Incision in Leg Hopewell, NJ (PRWEB) July 11, 2014 The Capital Institute for Neurosciences at Capital Health today announced it has performed the first procedure in a clinical trial that delivers chemotherapy to brain tumors through a catheter inserted in the leg. During the procedure, done at Capital Health Medical Center – Hopewell, Dr. Erol Veznedaroglu, an...

2014-07-09 11:17:04

NIH/National Institute of Neurological Disorders and Stroke NIH-funded researchers find brain tumor cells disrupt the brain's protective barrier, offering potential avenues for therapy Invading glioblastoma cells may hijack cerebral blood vessels during early stages of disease progression and damage the brain's protective barrier, a study in mice indicates. This finding could ultimately lead to new ways to bring about the death of the tumor, as therapies may be able to reach these...

2014-07-09 08:27:52

VANCOUVER, British Columbia and MENLO PARK, Calif., July 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced today that the company has been awarded a non-refundable financial contribution of up to CDN$194,000 from the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP). The research funded by this award will be conducted in collaboration with the University of British Columbia, the Vancouver Prostate Centre and...

2014-07-08 08:32:31

("Leading Edge" Gamma Knife Treatment, led by Christopher Duma, M.D., FACS and his team of researchers, offers hope to patients with Glioblastoma Multiforme) NEWPORT BEACH, Calif., July 8, 2014 /PRNewswire/ -- A study on the effects of an aggressive and strategic treatment called "Leading Edge" radiosurgery offers hope to patients diagnosed with life-threatening brain cancer. The study identifies the pathways of invasion of malignant glioma cells and provides a map in which a...

2014-07-07 10:11:17

McGill University Scientists at the Montreal Neurological Institute and Hospital, McGill University and McGill University Health Centre have shown that a member of the protein family known as SUMO (small ubiquitin-like modifier) is a key to why tumour cells multiply uncontrollably, especially in the case of glioblastoma. The SUMO family proteins modify other proteins and the SUMOylation of proteins are critical for many cellular processes. Identifying SUMO’s role in the cancer cell...

2014-07-02 16:24:28

In this phase two study, 50 percent of glioblastoma patients lived for two years, an encouraging result for one of the most deadly cancers that often kills patients within one year of diagnosis CHICAGO, July 2, 2014 /PRNewswire-USNewswire/ -- Patients newly diagnosed with glioblastoma multiforme (GBM) and treated with an experimental cancer vaccine made from the patient's own tumor in addition to standard of care lived longer compared to those who received standard of care alone,...

2014-06-30 08:30:17

SAN ANTONIO, June 30, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International presentation by Chairman and CEO, Craig Dionne, PhD from the 2014 BIO International Convention held June 24th in San Diego, California. Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study for lead drug candidate, G-202. Summary: -- G-202 Data in Hepatocellular (HCC) Patients...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'